news
Cell and gene therapy manufacturing services market to value $13.8 billion by 2026
The global cell and gene therapy manufacturing services market is expected to grow at a CAGR of 12.4 percent in the next five years.
List view / Grid view
Fujifilm
news
Fujifilm to launch rapid antigen COVID-19 test in Europe
Having received the CE certificate, Fujifilm can now launch its highly-sensitive, rapid antigen test kit for SARS-CoV-2 in Europe.
news
Clinical trials for COVID-19 treatments show mixed results, says study
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.
news
Influenza antiviral Avigan® (favipiravir) to enter Phase III trials in COVID-19 patients
The developers of Avigan have increased production and announced a Phase III clinical trial testing its efficacy against COVID-19.
Whitepapers/App Notes/Posters
Whitepaper: pAVEwayTM – microbial expression system for the efficient large scale production of therapeutic proteins
pAVEway™ is an innovative expression system in E. coli that enables rapid creation of novel recombinant strains and the development of downstream processes that ensure industry leading product titres and efficient scale-up of the production of proteins of therapeutic utility...
news
Fujifilm Diosynth Biotechnologies announce successful completion of its 100th paveway
Fujifilm Diosynth Biotechnologies has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system...
content_hub
Fujifilm
19 June 2017 | By
Fujifilm first penetrated into overseas markets primarily through its Imaging Solutions business. The company established a German subsidiary in charge of the comprehensive management of its European operations in 1966 and a manufacturing company in the Netherlands which was tasked with manufacturing color paper and color films in 1982. Today,…